首页> 外文OA文献 >Evaluation of MT1XT20 single quasi-monomorphic mononucleotide marker for characterizing microsatellite instability in persian lynch syndrome patients
【2h】

Evaluation of MT1XT20 single quasi-monomorphic mononucleotide marker for characterizing microsatellite instability in persian lynch syndrome patients

机译:评估MT1XT20单准单态单核苷酸标记物表征波斯lynch综合征患者的微卫星不稳定性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Colorectal malignancies with high microsatellite instability (MSI-H), either hereditary (Lynch syndrome) or sporadic, demonstrate better prognosis and altered response to 5FU chemotherapy. It is now recommended to perform MSI testing for all new cases of colorectal cancer regardless of being categorized as hereditary or sporadic. For MSI detection, immunohistochemistry or PCR-based protocols using a cohort of various sets of STR markers are recommended. Here we aimed to evaluate a simplified protocol using just a single STR marker, MT1XT20 mononucleotide repeat, for detection of MSI in Lynch syndrome patients. A Promega five-marker MSI testing panel and immunohistochemistry (IHC) were used as the gold standard in conjunction with MT1XT20. Materials and Methods: Colorectal patients with a positive history of familial cancers were selected by evaluating medical records. Based on Amsterdam II criteria for Lynch syndrome 20 families were short listed. DNA was extracted from formalin fixed paraffin embedded tumour and adjacent normal tissues resected from the index case in each family. Extracted DNA was subjected to MT1XT20 mononucleotide marker analysis and assessment with a commercially available five marker MSI testing kit (Promega, USA). IHC also was performed on tissue sections and the results were compared with PCR based data. Results: Eight (40%), seven (35%) and five (25%) cases were MSI positive using with the Promega kit, IHC and MT1XT20, respectively. Among the markers included in Promega kit, BAT26 marker showed instability in all 8 samples. NR24 and NR21 markers showed instability in 7 (87.5%), and BAT25 and MONO 27 in 6 (75%) and 5 (62.5%). Conclusions: Although MT1XT20 was earlier reported as a valid standalone marker for MSI testing in CRC patients, we could not verify this in our Iranian patients. Instead BAT26 among the markers included in Promega MSI testing kit showed instability in all 8 MSI-H CRC samples. Therefore, it seems BAT26 could act well as a single marker for MSI testing in Iranian CRC patients.
机译:背景:具有高微卫星不稳定性(MSI-H)的大肠恶性肿瘤(遗传性(Lynch综合征)或偶发性)表现出更好的预后并改变了对5FU化疗的反应。现在建议对所有新的结直肠癌病例进行MSI测试,而不管其是遗传性还是散发性。对于MSI检测,建议使用多种STR标记组队列的免疫组织化学或基于PCR的方案。在这里,我们旨在评估仅使用单个STR标记物MT1XT20单核苷酸重复序列的简化方案,以检测Lynch综合征患者的MSI。 Promega五标记MSI测试板和免疫组织化学(IHC)与MT1XT20一起用作黄金标准。材料和方法:通过评估病历选择具有家族性癌症阳性史的结直肠患者。根据阿姆斯特丹II类对林奇综合征的标准,入围了20个家庭。从福尔马林固定石蜡包埋的肿瘤以及从每个家庭的标本病例切除的邻近正常组织中提取DNA。使用市售的五标记MSI测试试剂盒(Promega,USA)对提取的DNA进行MT1XT20单核苷酸标记分析和评估。还对组织切片进行了IHC,并将结果与​​基于PCR的数据进行了比较。结果:分别使用Promega试剂盒,IHC和MT1XT20的MSI阳性病例为8(40%),7(35%)和5(25%)。在Promega试剂盒中包含的标记中,BAT26标记在所有8个样品中均显示不稳定。 NR24和NR21标记在7个(87.5%)中显示不稳定,BAT25和MONO 27在6个(75%)和5个(62.5%)中显示不稳定。结论:尽管更早地报道MT1XT20是CRC患者MSI测试的有效独立标记,但我们无法在伊朗患者中证实这一点。取而代之的是,Promega MSI测试套件中包括的标记中的BAT26在所有8个MSI-H CRC样本中均显示出不稳定。因此,在伊朗CRC患者中,BAT26似乎可以作为MSI测试的单一标记物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号